In a cohort of chronic hepatitis B patients, high concentrations of serum IL-38 (>250 pg/ml) at baseline were associated with a greater probability of viral response to treatment at 24 weeks (48.15% vs 15.79%) (29). This evidence concerns the gene IL1F10 and chronic hepatitis B virus infection.